Intensive LDL Reduction Post Acute Coronary Syndromes: A Catalyst for Improved Outcomes

Karam Kostner, Stephen Nicholls, John Amerena, Alex Brown, Mark Cooper, Chris Hammett, Richard O'Brien, Leonard Kritharides, David L. Hare, Gerald F. Watts, Philip Aylward

Research output: Contribution to journalEditorial

Abstract

There is overwhelming evidence that intensive statin therapy reduces atherogenic lipoproteins as well as cardiovascular events post acute coronary syndromes (ACS) [1], [2]. Furthermore, post-hoc analyses from randomised trials show that the benefit of statin therapy depends on the extent of LDL reduction [3]; patients achieving very low LDL cholesterol (LDL-C) levels in statin trials are at very low cardiovascular (CV) risk [4] and show no increased risk of adverse events related to the achievement of very low LDL-C levels.
Original languageEnglish
Pages (from-to)1051-1054
Number of pages4
JournalHeart Lung and Circulation
Volume25
Issue number11
DOIs
Publication statusPublished - 1 Nov 2016

Keywords

  • Coronary Syndromes
  • intensive LDL reduction
  • improved outcomes
  • post acute

Fingerprint Dive into the research topics of 'Intensive LDL Reduction Post Acute Coronary Syndromes: A Catalyst for Improved Outcomes'. Together they form a unique fingerprint.

  • Cite this

    Kostner, K., Nicholls, S., Amerena, J., Brown, A., Cooper, M., Hammett, C., O'Brien, R., Kritharides, L., Hare, D. L., Watts, G. F., & Aylward, P. (2016). Intensive LDL Reduction Post Acute Coronary Syndromes: A Catalyst for Improved Outcomes. Heart Lung and Circulation, 25(11), 1051-1054. https://doi.org/10.1016/j.hlc.2016.09.005